Skip to main content

Select Drug Profiles

The Use of Medicines in the United States: A Detailed Review

David B. Nash, MD, MBA

Practice Management

Current and Future Use of HEOR Data in Healthcare Decision-Making in the United States and in Emerging Markets

Anke-Peggy Holtorf, PhD, MBA, Diana Brixner, RPh, PhD, Brandon Bellows, PharmD, Abdulkadir Keskinaslan, MD, MBA, MPH, Joseph Dye, RPh, PhD, Gary Oderda, PharmD, MPH

Stakeholder Perspective

Health Economics and Outcomes Research Data Key in Coverage Decisions of New Medications

by Douglas S. Burgoyne, PharmD, FAMCP

Practice Management

The Policy-Driven Health Plan: A Road Map for Value-Based Reimbursement

Practice Management

Hematologic Complications, Healthcare Utilization, and Costs in Commercially Insured Patients with Myelodysplastic Syndrome Receiving Supportive Care

Annette Powers, PharmD, MBA, Claudio Faria, PharmD, MPH, Eunice Chang, PhD, Dasha Cherepanov, PhD, Jeffrey A. Bourret, PharmD

Stakeholder Perspective

Reconsidering the Management of Younger Patients with Myelodysplastic Syndrome

Getting Back to Reality: The Election, the Fiscal Cliff, and the ACA

Joseph R. Antos, PhD

APPENDIX: Detailed Methods

Real-Time Continuous Glucose Monitoring Cost-Effective in Patients with Type 2 Diabetes

Multiple Sclerosis: Patient Characteristics and Cost Concerns

Charles Bankhead, Medical Writer

Original Research

Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study

Barbara Lennert, RN, BSN, MAOM, Wendy Bibeau, PhD, Eileen Farrelly, MPH, Patricia Sacco, MPH, RPh, Tessa Schoor, MD

Stakeholder Perspective

Parkinson’s Disease: A Complicated but Underappreciated and Undertreated Condition

by Gary M. Owens, MD

Practice Management

Cost Management through Care Management, Part 2: The Importance of Managing Specialty Drug Utilization in the Medical Benefit

Michael T. Einodshofer, RPh, MBA, Lars N. Duren, BCNSP, PharmD

Page 190 of 244
Results 1891 - 1900 of 2438